Suppr超能文献

无定形格列齐特的物理化学研究及稳定性研究。

Physicochemical investigations and stability studies of amorphous gliclazide.

机构信息

Department of Pharmaceutical Chemistry, Government College of Pharmacy, Karad, Maharashtra, 415124, India.

出版信息

AAPS PharmSciTech. 2012 Jun;13(2):448-59. doi: 10.1208/s12249-012-9760-0. Epub 2012 Mar 2.

Abstract

Gliclazide (GLI), a poorly water-soluble antidiabetic, was transformed into a glassy state by melt quench technique in order to improve its physicochemical properties. Chemical stability of GLI during formation of glass was assessed by monitoring thin-layer chromatography, and an existence of amorphous form was confirmed by differential scanning calorimetry and X-ray powder diffractometry. The glass transition occurred at 67.5°C. The amorphous material thus generated was examined for its in vitro dissolution performance in phosphate buffer (pH 6.8). Surprisingly, amorphous GLI did not perform well and was unable to improve the dissolution characteristics compared to pure drug over entire period of dissolution studies. These unexpected results might be due to the formation of a cohesive supercooled liquid state and structural relaxation of amorphous form toward the supercooled liquid region which indicated functional inability of amorphous GLI from stability point of view. Hence, stabilization of amorphous GLI was attempted by elevation of T(g) via formation of solid dispersion systems involving comprehensive antiplasticizing as well as surface adsorption mechanisms. The binary and ternary amorphous dispersions prepared with polyvinylpyrrolidone K30 (as antiplasticizer for elevation of T (g)) and Aerosil 200® and/or Sylysia® 350 (as adsorbent) in the ratio of 1:1:1 (w/w) using kneading and spray-drying techniques demonstrated significant enhancement in rate and extent of dissolution of drug initially. During accelerated stability studies, ternary systems showed no significant reduction in drug dissolution performance over a period of 3 months indicating excellent stabilization of amorphous GLI.

摘要

格列齐特(GLI)是一种水溶性较差的抗糖尿病药物,通过熔融淬火技术将其转化为玻璃态,以改善其物理化学性质。通过监测薄层色谱法评估 GLI 在形成玻璃过程中的化学稳定性,并通过差示扫描量热法和 X 射线粉末衍射法确认存在无定形形式。玻璃化转变发生在 67.5°C。因此,对生成的无定形材料进行了在磷酸盐缓冲液(pH 6.8)中的体外溶解性能研究。令人惊讶的是,与纯药物相比,无定形 GLI 在整个溶解研究期间并不能改善其溶解特性。这些意外的结果可能是由于形成了有凝聚力的过冷液体状态和无定形形式向过冷液体区域的结构松弛,这表明从稳定性的角度来看,无定形 GLI 的功能丧失。因此,通过形成涉及全面抗塑化以及表面吸附机制的固体分散系统来提高 T(g),尝试稳定无定形 GLI。使用 kneading 和喷雾干燥技术以 1:1:1(w/w)的比例制备的包含聚乙烯吡咯烷酮 K30(作为提高 T(g)的抗塑化剂)和 Aerosil 200®和/或 Sylysia®350(作为吸附剂)的二元和三元无定形分散体在初始时显著提高了药物的溶解速率和程度。在加速稳定性研究中,三元系统在 3 个月的时间内没有显示出药物溶解性能的显著降低,表明无定形 GLI 得到了很好的稳定。

相似文献

1
Physicochemical investigations and stability studies of amorphous gliclazide.
AAPS PharmSciTech. 2012 Jun;13(2):448-59. doi: 10.1208/s12249-012-9760-0. Epub 2012 Mar 2.
2
In vitro evaluation and in vivo performance of lyophilized gliclazide.
Drug Dev Ind Pharm. 2015 Apr;41(4):650-7. doi: 10.3109/03639045.2014.891131. Epub 2014 Feb 26.
3
Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000.
AAPS PharmSciTech. 2008;9(2):563-70. doi: 10.1208/s12249-008-9079-z. Epub 2008 May 6.
4
Evaluation of colloidal solid dispersions: physiochemical considerations and in vitro release profile.
AAPS PharmSciTech. 2013 Jun;14(2):620-8. doi: 10.1208/s12249-013-9947-z. Epub 2013 Mar 15.
8
The Stabilization of Amorphous Zopiclone in an Amorphous Solid Dispersion.
AAPS PharmSciTech. 2015 Oct;16(5):1190-202. doi: 10.1208/s12249-015-0302-4. Epub 2015 Mar 4.
9
Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
J Pharm Pharmacol. 2016 May;68(5):615-24. doi: 10.1111/jphp.12458. Epub 2015 Aug 5.
10

引用本文的文献

1
Physicochemical reports of gliclazide-carplex solid dispersions and tablets prepared with directly compressible co-processed excipients.
Heliyon. 2023 Nov 26;9(12):e22899. doi: 10.1016/j.heliyon.2023.e22899. eCollection 2023 Dec.
3
Screening of Sacrificial Excipients for Arresting Devitrification of Itraconazole from Solid Dispersion.
Turk J Pharm Sci. 2019 Jun;16(2):211-219. doi: 10.4274/tjps.galenos.2018.54871. Epub 2019 Mar 27.
5
Novel Gliclazide Electrosprayed Nano-Solid Dispersions: Physicochemical Characterization and Dissolution Evaluation.
Adv Pharm Bull. 2019 Jun;9(2):231-240. doi: 10.15171/apb.2019.026. Epub 2019 Jun 1.
6
The Need for Restructuring the Disordered Science of Amorphous Drug Formulations.
Pharm Res. 2017 Sep;34(9):1754-1772. doi: 10.1007/s11095-017-2174-7. Epub 2017 May 18.
8
Preparation, characterization, and in vivo evaluation of tanshinone IIA solid dispersions with silica nanoparticles.
Int J Nanomedicine. 2013;8:2285-93. doi: 10.2147/IJN.S40374. Epub 2013 Jun 25.
9
Studies on tolfenamic acid-chitosan intermolecular interactions: effect of pH, polymer concentration and molecular weight.
AAPS PharmSciTech. 2013 Jun;14(2):870-9. doi: 10.1208/s12249-013-9974-9. Epub 2013 Apr 27.

本文引用的文献

2
Co-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients.
Indian J Pharm Sci. 2009 Jul;71(4):359-70. doi: 10.4103/0250-474X.57283.
3
Physicochemical properties of solid dispersions of gliclazide in polyvinylpyrrolidone K90.
AAPS PharmSciTech. 2009;10(2):329-34. doi: 10.1208/s12249-009-9212-7. Epub 2009 Mar 25.
4
Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000.
AAPS PharmSciTech. 2008;9(2):563-70. doi: 10.1208/s12249-008-9079-z. Epub 2008 May 6.
5
Polymorph control: past, present and future.
Drug Discov Today. 2008 Mar;13(5-6):198-210. doi: 10.1016/j.drudis.2007.11.006. Epub 2008 Jan 14.
6
Application of polyglycolized glycerides in protection of amorphous form of etoricoxib during compression.
Chem Pharm Bull (Tokyo). 2007 Oct;55(10):1448-51. doi: 10.1248/cpb.55.1448.
9
Stabilization and improved in vivo performance of amorphous etoricoxib using Gelucire 50/13.
Pharm Res. 2005 Oct;22(10):1727-34. doi: 10.1007/s11095-005-6694-1. Epub 2005 Sep 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验